Dieter A. Häring

Ofatumumab versus Teriflunomide in Multiple Sclerosis

Stephen L. Hauser, Amit Bar‐Or, Jeffrey Cohen et al. · New England Journal of Medicine · 2020 · 700 citations · Full text

Life Sciences, Immunology, Pharmacology +17

How patients with multiple sclerosis acquire disability

Fred Lublin, Dieter A. Häring, Habib Ganjgahi et al. · Brain · 2022 · 528 citations · Full text

Education, Neurology, Disability Management +13

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

Fred Lublin, David H. Miller, Mark S. Freedman et al. · The Lancet · 2016 · 449 citations · Full text

Medicine, Neurology, Pharmacotherapy +10

Inclusion of brain volume loss in a revised measure of ‘no evidence of disease activity’ (NEDA-4) in relapsing–remitting multiple sclerosis

Ludwig Kappos, Nicola De Stefano, Mark S. Freedman et al. · Multiple Sclerosis Journal · 2016 · 288 citations · Full text

Life Sciences, Neurology, Neuroscience +16

Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years

Ester Cantó, Christian Barro, Chao Zhao et al. · JAMA Neurology · 2019 · 195 citations · Full text

Life Sciences, Neurology, Neuroscience +17